Bone marrow biopsy during induction chemotherapy for acute myeloid leukaemia identifies only 50% of patients with resistant disease
A study was carried out to determine whether bone marrow biopsy performed on day 6 of induction therapy for acute myeloid leukaemia (AML) can identify those patients with resistant disease who would need an intensification of the first course of induction. Bone marrow biopsies were performed on day...
Gespeichert in:
| Veröffentlicht in: | Leukemia research 1988, Vol.12 (10), p.817-821 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 821 |
|---|---|
| container_issue | 10 |
| container_start_page | 817 |
| container_title | Leukemia research |
| container_volume | 12 |
| creator | Roberts, Marion M. Juttner, Christopher A. To, L.Bik Kimber, Richard J. |
| description | A study was carried out to determine whether bone marrow biopsy performed on day 6 of induction therapy for acute myeloid leukaemia (AML) can identify those patients with resistant disease who would need an intensification of the first course of induction. Bone marrow biopsies were performed on day 6 of induction chemotherapy in 44 patients with AML treated with daunorubicin, cytosine arabinoside and thioguanine. Biopsies were assessed for blast count, trephine cellularity and leukaemic index. Discrimination between patients who went on to achieve remission and those with resistant disease was best achieved using the reduction in bone marrow cellularity from pretreatment marrow to day-6 marrow. However, this discriminator identified only 50% of the patients with resistant disease and included 13% of patients who achieved remission with the first course of chemotherapy. The other parameters of response were even less effective at discriminating between chemotherapy-resistant and chemotherapy-responsive disease. |
| doi_str_mv | 10.1016/0145-2126(88)90035-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78575950</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0145212688900355</els_id><sourcerecordid>78575950</sourcerecordid><originalsourceid>FETCH-LOGICAL-c301t-a0e28d9ae020a5ef7fb27fc2f7a5e90c8e00c8d22ca9e2b2dff4c2ced964efd13</originalsourceid><addsrcrecordid>eNp9kM2OFCEURonRjD2jb6AJC53oohSoogo2JjrxL5nEja4JDRf7alXRAuWk1r64tN3ppRsI-c53czmEPOHsFWe8f814JxvBRf9CqZeasVY28h7ZcDW0jVStvE82Z-Qhucz5B2NMaq4vyEXLtVYd35A_7-IMdLIpxTu6xbjPK_VLwvk7xdkvrmCcqdvBFMsOkt2vNMRErVtKba0wRvR0hOWnhQktRQ9zwYCQaZzHlUr2nMZA97ZgDTK9w7KjCTLmYudCPWawGR6RB8GOGR6f7ivy7cP7rzefmtsvHz_fvL1tXMt4aSwDoby2wASzEsIQtmIIToShvjRzClg9vBDOahBb4UPonHDgdd9B8Ly9ItfHufsUfy2Qi5kwOxhHO0NcshmUHKSWrILdEXQp5pwgmH3C6mg1nJmDe3MQaw5ijVLmn3sja-3paf6yncCfSyfZNX92ym12dgzJzg7zGRtYr4XoK_bmiEF18RshmeyqvvoRTOCK8RH_v8dfUeejww</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78575950</pqid></control><display><type>article</type><title>Bone marrow biopsy during induction chemotherapy for acute myeloid leukaemia identifies only 50% of patients with resistant disease</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Roberts, Marion M. ; Juttner, Christopher A. ; To, L.Bik ; Kimber, Richard J.</creator><creatorcontrib>Roberts, Marion M. ; Juttner, Christopher A. ; To, L.Bik ; Kimber, Richard J.</creatorcontrib><description>A study was carried out to determine whether bone marrow biopsy performed on day 6 of induction therapy for acute myeloid leukaemia (AML) can identify those patients with resistant disease who would need an intensification of the first course of induction. Bone marrow biopsies were performed on day 6 of induction chemotherapy in 44 patients with AML treated with daunorubicin, cytosine arabinoside and thioguanine. Biopsies were assessed for blast count, trephine cellularity and leukaemic index. Discrimination between patients who went on to achieve remission and those with resistant disease was best achieved using the reduction in bone marrow cellularity from pretreatment marrow to day-6 marrow. However, this discriminator identified only 50% of the patients with resistant disease and included 13% of patients who achieved remission with the first course of chemotherapy. The other parameters of response were even less effective at discriminating between chemotherapy-resistant and chemotherapy-responsive disease.</description><identifier>ISSN: 0145-2126</identifier><identifier>EISSN: 1873-5835</identifier><identifier>DOI: 10.1016/0145-2126(88)90035-5</identifier><identifier>PMID: 3199841</identifier><identifier>CODEN: LEREDD</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Acute myeloid leukaemia ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Biopsy ; Bone Marrow - pathology ; Bone Marrow Examination ; Chemotherapy ; Cytarabine - administration & dosage ; Daunorubicin - administration & dosage ; day-6 bone marrow biopsy ; Drug Resistance ; Humans ; induction ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - pathology ; Medical sciences ; Pharmacology. Drug treatments ; Remission Induction ; Thioguanine - administration & dosage</subject><ispartof>Leukemia research, 1988, Vol.12 (10), p.817-821</ispartof><rights>1988</rights><rights>1989 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c301t-a0e28d9ae020a5ef7fb27fc2f7a5e90c8e00c8d22ca9e2b2dff4c2ced964efd13</citedby><cites>FETCH-LOGICAL-c301t-a0e28d9ae020a5ef7fb27fc2f7a5e90c8e00c8d22ca9e2b2dff4c2ced964efd13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0145212688900355$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,4010,27900,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7069226$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3199841$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roberts, Marion M.</creatorcontrib><creatorcontrib>Juttner, Christopher A.</creatorcontrib><creatorcontrib>To, L.Bik</creatorcontrib><creatorcontrib>Kimber, Richard J.</creatorcontrib><title>Bone marrow biopsy during induction chemotherapy for acute myeloid leukaemia identifies only 50% of patients with resistant disease</title><title>Leukemia research</title><addtitle>Leuk Res</addtitle><description>A study was carried out to determine whether bone marrow biopsy performed on day 6 of induction therapy for acute myeloid leukaemia (AML) can identify those patients with resistant disease who would need an intensification of the first course of induction. Bone marrow biopsies were performed on day 6 of induction chemotherapy in 44 patients with AML treated with daunorubicin, cytosine arabinoside and thioguanine. Biopsies were assessed for blast count, trephine cellularity and leukaemic index. Discrimination between patients who went on to achieve remission and those with resistant disease was best achieved using the reduction in bone marrow cellularity from pretreatment marrow to day-6 marrow. However, this discriminator identified only 50% of the patients with resistant disease and included 13% of patients who achieved remission with the first course of chemotherapy. The other parameters of response were even less effective at discriminating between chemotherapy-resistant and chemotherapy-responsive disease.</description><subject>Acute myeloid leukaemia</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biopsy</subject><subject>Bone Marrow - pathology</subject><subject>Bone Marrow Examination</subject><subject>Chemotherapy</subject><subject>Cytarabine - administration & dosage</subject><subject>Daunorubicin - administration & dosage</subject><subject>day-6 bone marrow biopsy</subject><subject>Drug Resistance</subject><subject>Humans</subject><subject>induction</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - pathology</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Remission Induction</subject><subject>Thioguanine - administration & dosage</subject><issn>0145-2126</issn><issn>1873-5835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM2OFCEURonRjD2jb6AJC53oohSoogo2JjrxL5nEja4JDRf7alXRAuWk1r64tN3ppRsI-c53czmEPOHsFWe8f814JxvBRf9CqZeasVY28h7ZcDW0jVStvE82Z-Qhucz5B2NMaq4vyEXLtVYd35A_7-IMdLIpxTu6xbjPK_VLwvk7xdkvrmCcqdvBFMsOkt2vNMRErVtKba0wRvR0hOWnhQktRQ9zwYCQaZzHlUr2nMZA97ZgDTK9w7KjCTLmYudCPWawGR6RB8GOGR6f7ivy7cP7rzefmtsvHz_fvL1tXMt4aSwDoby2wASzEsIQtmIIToShvjRzClg9vBDOahBb4UPonHDgdd9B8Ly9ItfHufsUfy2Qi5kwOxhHO0NcshmUHKSWrILdEXQp5pwgmH3C6mg1nJmDe3MQaw5ijVLmn3sja-3paf6yncCfSyfZNX92ym12dgzJzg7zGRtYr4XoK_bmiEF18RshmeyqvvoRTOCK8RH_v8dfUeejww</recordid><startdate>1988</startdate><enddate>1988</enddate><creator>Roberts, Marion M.</creator><creator>Juttner, Christopher A.</creator><creator>To, L.Bik</creator><creator>Kimber, Richard J.</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1988</creationdate><title>Bone marrow biopsy during induction chemotherapy for acute myeloid leukaemia identifies only 50% of patients with resistant disease</title><author>Roberts, Marion M. ; Juttner, Christopher A. ; To, L.Bik ; Kimber, Richard J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c301t-a0e28d9ae020a5ef7fb27fc2f7a5e90c8e00c8d22ca9e2b2dff4c2ced964efd13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Acute myeloid leukaemia</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biopsy</topic><topic>Bone Marrow - pathology</topic><topic>Bone Marrow Examination</topic><topic>Chemotherapy</topic><topic>Cytarabine - administration & dosage</topic><topic>Daunorubicin - administration & dosage</topic><topic>day-6 bone marrow biopsy</topic><topic>Drug Resistance</topic><topic>Humans</topic><topic>induction</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - pathology</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Remission Induction</topic><topic>Thioguanine - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roberts, Marion M.</creatorcontrib><creatorcontrib>Juttner, Christopher A.</creatorcontrib><creatorcontrib>To, L.Bik</creatorcontrib><creatorcontrib>Kimber, Richard J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roberts, Marion M.</au><au>Juttner, Christopher A.</au><au>To, L.Bik</au><au>Kimber, Richard J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bone marrow biopsy during induction chemotherapy for acute myeloid leukaemia identifies only 50% of patients with resistant disease</atitle><jtitle>Leukemia research</jtitle><addtitle>Leuk Res</addtitle><date>1988</date><risdate>1988</risdate><volume>12</volume><issue>10</issue><spage>817</spage><epage>821</epage><pages>817-821</pages><issn>0145-2126</issn><eissn>1873-5835</eissn><coden>LEREDD</coden><abstract>A study was carried out to determine whether bone marrow biopsy performed on day 6 of induction therapy for acute myeloid leukaemia (AML) can identify those patients with resistant disease who would need an intensification of the first course of induction. Bone marrow biopsies were performed on day 6 of induction chemotherapy in 44 patients with AML treated with daunorubicin, cytosine arabinoside and thioguanine. Biopsies were assessed for blast count, trephine cellularity and leukaemic index. Discrimination between patients who went on to achieve remission and those with resistant disease was best achieved using the reduction in bone marrow cellularity from pretreatment marrow to day-6 marrow. However, this discriminator identified only 50% of the patients with resistant disease and included 13% of patients who achieved remission with the first course of chemotherapy. The other parameters of response were even less effective at discriminating between chemotherapy-resistant and chemotherapy-responsive disease.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>3199841</pmid><doi>10.1016/0145-2126(88)90035-5</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0145-2126 |
| ispartof | Leukemia research, 1988, Vol.12 (10), p.817-821 |
| issn | 0145-2126 1873-5835 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78575950 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Acute myeloid leukaemia Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Biopsy Bone Marrow - pathology Bone Marrow Examination Chemotherapy Cytarabine - administration & dosage Daunorubicin - administration & dosage day-6 bone marrow biopsy Drug Resistance Humans induction Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - pathology Medical sciences Pharmacology. Drug treatments Remission Induction Thioguanine - administration & dosage |
| title | Bone marrow biopsy during induction chemotherapy for acute myeloid leukaemia identifies only 50% of patients with resistant disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T14%3A28%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bone%20marrow%20biopsy%20during%20induction%20chemotherapy%20for%20acute%20myeloid%20leukaemia%20identifies%20only%2050%25%20of%20patients%20with%20resistant%20disease&rft.jtitle=Leukemia%20research&rft.au=Roberts,%20Marion%20M.&rft.date=1988&rft.volume=12&rft.issue=10&rft.spage=817&rft.epage=821&rft.pages=817-821&rft.issn=0145-2126&rft.eissn=1873-5835&rft.coden=LEREDD&rft_id=info:doi/10.1016/0145-2126(88)90035-5&rft_dat=%3Cproquest_cross%3E78575950%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78575950&rft_id=info:pmid/3199841&rft_els_id=0145212688900355&rfr_iscdi=true |